Novo Nordisk A/s

This Phase 3 study tests whether a weekly injection called zenagamtide helps Asian adults with overweight or obesity lose weight safely. About 400 participants will receive either the drug or a placebo for several weeks. The main goal is to see how much body weight changes, with …

This study tests a new medicine called UBT251, given as a weekly shot, in 300 adults with type 2 diabetes. Some participants will get UBT251, others will get a placebo or an existing drug (semaglutide). The goal is to see if UBT251 can safely lower blood sugar and help with weigh…

This Phase 3 trial will test whether a new drug called zenagamtide helps people with obesity lose more weight than the current treatment semaglutide. About 650 adults will receive weekly injections of either zenagamtide, semaglutide, or a placebo. The main goal is to see how much…

This study looks at how well a new once-weekly insulin, called insulin icodec, works for people with type 2 diabetes who are switching from a daily insulin. Researchers will track blood sugar control, treatment satisfaction, and how well patients stick to the new regimen over abo…

This study tests a new medicine called NNC0662-0419 in 230 adults with obesity (BMI 30 or higher). Researchers want to see if different ways of increasing the dose over time can reduce stomach side effects while still helping people lose at least 25% of their body weight. The stu…

This study looks at how well a new insulin called icodec controls blood sugar in adults with type 2 diabetes who are switching from their current daily insulin. About 214 participants in Italy will use icodec as prescribed by their doctor for 22 to 30 weeks. Researchers will meas…

This study tests a once-weekly injection called CagriSema (a mix of cagrilintide and semaglutide) in 80 children and adolescents with type 2 diabetes. The goal is to see if it lowers blood sugar and body weight better than a placebo. The trial lasts about 15 months, with everyone…

This early-stage study will compare two different versions of the drug cagrilintide in 50 adults with overweight or obesity. Participants will receive injections of either version for several weeks, and researchers will measure how the drug builds up in the body. The goal is to s…

This study tests a new medicine called CagriSema, which combines two drugs to lower blood sugar in people with type 2 diabetes. About 400 adults aged 18-64 will receive either CagriSema or a placebo using one of two injection devices. The main goal is to see how well it reduces H…

This Phase 3 trial tests a new once-weekly injection, NNC0487-0111, against the approved drug semaglutide in 1000 adults with overweight or obesity and type 2 diabetes. Participants receive two weekly shots (active drug plus placebo) to see if the new drug is safe and leads to gr…

This study tests a new medicine called CagriSema to help people with overweight or obesity lose weight. About 1,400 adults will receive either CagriSema or a placebo for around one year. The main goal is to see how much weight they lose and check for any side effects.

This study looks at the safety and effectiveness of Rybelsus, a pill for type 2 diabetes, in everyday medical practice in Korea. About 600 adults will take the medicine as their doctor prescribes, and researchers will track side effects and blood sugar control for 26 weeks. The g…

This study asks adults with haemophilia A in Germany to complete an online survey about their preferences for preventive treatments. Participants choose between hypothetical treatment options that vary in effectiveness, safety, and how they are given. The goal is to understand wh…

This study will follow 100 adults with X-linked hypophosphatemia (XLH) who are already taking burosumab. Researchers want to see how phosphate levels change over time and how they relate to bone health and overall disease burden. The goal is to better understand the condition and…

This early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…